| Literature DB >> 34972974 |
Mehmet Altan1, Linda Zhong2, Vickie R Shannon3, Ajay Sheshadri3.
Abstract
Immune checkpoint inhibitors are a form of immunotherapy that are increasingly being used in a wide variety of cancers. Immune-related adverse events (irAEs) pose a major challenge in the treatment of cancer patients. Pneumonitis, the most common lung irAE, can cause significant disruptions in the treatment of cancer and may be life-threatening. The goal of this chapter is to instruct readers on the incidence and clinical manifestations of pneumonitis and to offer guidance in the evaluation and treatment of patients with pneumonitis.Entities:
Keywords: Checkpoint inhibitors; Diffuse alveolar damage; Hypersensitivity pneumonitis; Immune-related adverse event; Nonspecific interstitial pneumonia; Organizing pneumonia; Pneumonitis; Thoracic imaging
Mesh：
Substances：
Year: 2021 PMID： 34972974 DOI： 10.1007/978-3-030-79308-1_14
Source DB: PubMed Journal: Adv Exp Med Biol ISSN： 0065-2598 Impact factor: 2.622